Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL

ByMazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

June 26th 2023

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

Dr Shadman on Zanubrutinib in Acalabrutinib-Intolerant Patients With B-cell Malignancies

ByMazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

December 11th 2022

Mazyar Shadman, MD, MPH, discusses the examination of zanubrutinib in patients with B-cell malignancies who were intolerant to acalabrutinib.

Future Directions in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

PI3 Kinase Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapeutic Sequencing in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

MURANO Trial Update in R/R CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Utility of MRD Testing in CLL Management

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax and Obinutuzumab in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Second-Generation BTK Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapies in the Pipeline for Frontline CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Telemedicine for Patients With CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Treating CLL During COVID-19

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Frontline Treatment Options in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

COVID-19 and CLL Treatment Initiation

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting First-Line Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Advances in Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Impact of COVID-19 on Management of CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Dr. Shadman on the Efficacy of Venetoclax in CLL

ByMazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

August 20th 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the efficacy of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Dr. Shadman on the CLL14 Trial in CLL

ByMazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

July 19th 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the phase III CLL14 trial in chronic lymphocytic leukemia (CLL).

Dr. Shadman on Fixed Durations of Treatment in CLL

ByMazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

July 9th 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington School of Medicine, and attending physician, Seattle Cancer Care Alliance, discusses fixed durations of treatment in chronic lymphocytic leukemia (CLL).